Drugs / Vonafexor
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06939816 | Jul → Dec 2025 | chronic kidney disease, metabolic dysfunction-associated steatohepatitis | Enyo Pharma | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT06425055 | Aug 2024 → Sep 2025 | Alport syndrome | Enyo Pharma | Completed | No outcome recorded |
| Phase 2 | NCT03812029 | Jan 2019 → Jun 2021 | metabolic dysfunction-associated steatohepatitis | Enyo Pharma | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-09-06 | Enyo Pharma | Regulatory Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) enyopharma.com ↗
ENYO Pharma announces that both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation (ODD) to Vonafexor, our fibrolytic & anti-inflammatory clinical compound, for the treatment of Alport syndrome. |
| 2022-12-29 | Enyo Pharma | Results New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH enyopharma.com ↗
ENYO Pharma is proud to share the publication of the results from our Phase 2 LIVIFY study with Vonafexor in NASH patients in Journal of Hepatology. |
| 2020-11-19 | Enyo Pharma | Regulatory Vonafexor accepted as the generic name for EYP001 by the WHO enyopharma.com ↗
We are pleased to announce that the World Health Organization (WHO) has accepted the international non-proprietary name (INN, or generic name) vonafexor for our FXR agonist lead candidate previously referred to as EYP001. |
All press releases naming this drug 5 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vonafexor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03812029 ↗ |
| Known as | EYP001a | “The purpose of this study is to assess the effects of EYP001a (Vonafexor) with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in...” NCT03812029 ↗ |
| Action | Activate | “vonafexor, a second-generation, non-bile acid farnesoid X receptor agonist” PMID 36334688 ↗ Nov 2022 |
| Modality | Small molecule | — CHEMBL5314935 ↗ |
| Route | Oral | “single daily administration of oral vonafexor” PMID 36334688 ↗ Nov 2022 |